Caribou Biosciences, Inc. (CRBU)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 4.69M | $7.46M | $7.97M | $515,947.88 | 6.92% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 47,908 | $84,320 | $79,048.2 | -$5,271.8 | -6.25% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,135 | $4,906.9 | $1,918.15 | -$2,988.75 | -60.91% |
| BG Bart Gancher Intech Investment Management LLC | 19,870 | $35,169.9 | $32,785.5 | -$2,384.4 | -6.78% |
 Robert Bruce Robert Jeffrey Bruce is VP/Secretary at Bruce & Co Inc. | 250,000 | $854,500 | $395,000 | -$459,500 | -53.77% |
Caribou Biosciences, Inc. (CRBU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Caribou Biosciences, Inc. ever had a stock split?
Caribou Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rachel E. Haurwitz CEO | NASDAQ (NGS) Exchange | 142038108 CUSIP |
| US Country | 97 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Caribou Biosciences, Inc. is a pioneering clinical-stage biopharmaceutical company based in the United States, with international operations, focused on the advancement of genome-edited allogeneic cell therapies. These innovative therapies are designed to combat hematologic malignancies, offering new hope in the fight against challenging diseases. Founded in 2011 and with its headquarters nestled in Berkeley, California, Caribou Biosciences is at the forefront of leveraging cutting-edge biotechnological methodologies to develop treatments that could potentially transform the therapeutic landscape for patients battling blood cancers.
Products and Services
- CB-010 - An allogeneic anti-CD19 CAR-T cell therapy that is currently undergoing a phase 1 clinical trial. This flagship product candidate represents Caribou Biosciences' commitment to pioneering the development of cell therapies. It is specifically designed to treat relapsed or refractory B cell non-Hodgkin lymphoma, targeting the CD19 antigen, a known marker associated with this type of cancer. CB-010 stands out as a beacon of hope for patients who have exhausted other therapeutic options, offering a novel, potentially life-saving treatment modality.
- CB-011 - This allogeneic anti-BCMA CAR-T cell therapy is another innovative product from Caribou Biosciences' pipeline, currently in a phase 1 clinical trial. Specifically tailored for the treatment of relapsed or refractory multiple myeloma, CB-011 targets the BCMA (B-cell maturation antigen), a key player in the progression of multiple myeloma. By focusing on this specific antigen, CB-011 holds the promise of introducing a revolutionary therapeutic option for patients grappling with this challenging disease.
- CB-012 - Rounding out Caribou Biosciences' groundbreaking portfolio is CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is also in phase 1 clinical trial. Dedicated to the treatment of relapsed or refractory acute myeloid leukemia (AML), CB-012 targets CD371, an antigen associated with AML. This cutting-edge therapy embodies the company’s dedication to expanding its impact across different types of hematologic malignancies, offering potential new treatment avenues for patients with AML.
